Literature DB >> 16724171

[Legal requirements for the coating of coronary stents with medications by cardiologists outside clinical investigations. Information of the Federal Institute for Medications and Medical Products and the central position of the various regions for health preservation in using medications and medical products (ZLG)].

Dirk von Mallek1, I Tolle, K Stephan, R Edelhäuser, B Heinz.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16724171     DOI: 10.1007/s00392-006-0409-4

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  3 in total

1.  [Position paper on the use of drug eluting stents (DES) in percutaneous coronary interventions in patients with coronary heart disease].

Authors:  B Levenson
Journal:  Z Kardiol       Date:  2003-07

2.  Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting.

Authors:  B Scheller; A Schmitt; M Böhm; G Nickenig
Journal:  Z Kardiol       Date:  2003-12

Review 3.  [When are drug-eluting stents effective? A critical analysis of the presently available data].

Authors:  S Silber
Journal:  Z Kardiol       Date:  2004-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.